Raymond James is acting as lead financial advisor and Citi as financial advisor to ZO Skin Health and Blackstone, while Weil, Gotshal & Manges LLP and Paul, Weiss are serving as legal counsel.

USA – Galderma has agreed to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone Tactical Opportunities and the Obagi family.
The transaction will see Galderma purchase 100% of ZO Skin Health for an enterprise value of USD 1.5 billion in an all-cash deal, subject to customary adjustments, with funding provided through a combination of Galderma’s existing cash reserves and bank financing.
The acquisition is expected to close in the fourth quarter of 2026 or early 2027, pending regulatory approvals and other customary closing conditions.
Flemming Ørnskov, M.D., MPH, Chief Executive Officer of Galderma, said, “This acquisition is another important step towards building the world’s most innovative dermatology portfolio, strengthening our offering in an area where we already have significant capabilities.”
“ZO Skin Health brings strong clinical credentials, a distinctive protocol-based approach and a trusted position among dermatologists and plastic surgeons.”
Founded by dermatologist Dr. Zein Obagi and headquartered in Irvine, California, ZO Skin Health has been a recognized leader in clinically backed professional skincare for more than two decades.
The company offers a portfolio of more than 40 products, all manufactured in the United States, and sells through a network of over 16,500 physician, medical spa, and online accounts across more than 40 countries.
Its operations are supported by a dedicated salesforce and skincare education team, and the business recorded net sales of approximately USD 330 million in the twelve months ended June 2026.
The acquisition brings together two highly complementary skincare businesses.
ZO Skin Health’s premium daily multi-step regimens, centred on retinol- and acid-based protocols, complement Alastin’s regenerative skincare portfolio, which focuses primarily on peri-procedure support through peptide-based pre- and post-procedure products.
By combining these offerings, Galderma aims to strengthen its Dermatological Skincare portfolio, which already includes Cetaphil® and Alastin®, and to enhance its position as a preferred partner for dermatologists, plastic surgeons, and aesthetic professionals.
Galderma believes that its Integrated Dermatology Strategy, global scale, and omni-channel execution capabilities will support ZO Skin Health’s next phase of growth.
The company plans to increase commercial investment during the first year of ownership to establish a stronger foundation for renewed growth beginning in the second year after closing.
Galderma views the transaction as an important step in expanding its presence in the attractive and fast-growing physician-dispensed skincare segment.
From a financial perspective, the transaction is expected to be Core EPS neutral in the first full year following closing.
It is also expected to be slightly dilutive to Galderma’s Group Core EBITDA margin in 2027, before achieving a margin broadly comparable with the Group’s average from 2028 onward.
According to Galderma, the acquisition remains consistent with its commitment to maintaining a solid investment-grade credit rating. Lazard is acting as lead financial advisor and J.P. Morgan as financial advisor to Galderma, with Ropes & Gray LLP serving as legal advisor.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.